Trevena Inc., of Chesterbrook, Pa., may be looking for some pain relief of its own after the FDA's release of briefing documents ahead of a Thursday adcom triggered a landslide Tuesday for the company hoping to score its first win with Olinvo (oliceridine), an injectable opioid receptor mu agonist developed to treat moderate to severe acute pain. After closing at $2.98 Monday, shares of Trevena (NASDAQ:TRVN) tumbled more than 67 percent Tuesday, hitting an all-time low of 97 cents.